Statement of Organization, Functions, and Delegations of Authority, 7725 [2021-02093]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 19 / Monday, February 1, 2021 / Notices
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
CE21–004: Research Grants for
Preventing Violence and Violence
Related Injury.
Date: May 25–26, 2021.
Time: 8:30 a.m.–5:00 p.m., EDT.
Place: Videoconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Mikel Walters, Ph.D., Scientific Review
Officer, National Center for Injury
Prevention and Control, CDC, 4770
Buford Highway NE, Mailstop F–63,
Atlanta, Georgia 30341, Telephone (404)
639–0913, MWalters@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
CE21–005, The CDC National Centers of
Excellence in Youth Violence
Prevention (YVPCs): Rigorous
Evaluation of Prevention Strategies to
Prevent and Reduce Community Rates
of Youth Violence.
Date: June 22–24, 2021.
Time: 8:30 a.m.–5:00 p.m., EDT.
Place: Web Conference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact:
Mikel Walters, Ph.D., Scientific Review
Officer, National Center for Injury
Prevention and Control, CDC, 4770
Buford Highway NE, Mailstop F–63,
Atlanta, Georgia 30341, Telephone (404)
639–0913, MWalters@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
[FR Doc. 2021–02051 Filed 1–29–21; 8:45 am]
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
BILLING CODE 4163–18–P
[FR Doc. 2021–02054 Filed 1–29–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
VerDate Sep<11>2014
16:57 Jan 29, 2021
Jkt 253001
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 86 FR 6336–6340, dated
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
7725
January 20, 2021) is amended to reflect
the Order of Succession for the Centers
for Disease Control and Prevention.
Section C–C, Order of Succession, is
hereby amended as follows:
Delete in its entirety Section C–C,
Order of Succession, and insert the
following:
During the absence or disability of the
Director, Centers for Disease Control
and Prevention (CDC), or in the event of
a vacancy in that office, the first official
listed below who is available shall act
as Director, except that during a
planned period of absence, the Director
may specify a different order of
succession:
1. Principal Deputy Director
2. Chief Medical Officer
3. Deputy Director for Public Health
Service and Implementation
Science
4. Deputy Director for Infectious
Diseases
5. Deputy Director for Public Health
Science and Surveillance
6. Deputy Director for Non-Infectious
Diseases
7. Director, National Institute for
Occupational Safety and Health
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2021–02093 Filed 1–29–21; 8:45 am]
BILLING CODE 4160–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
E:\FR\FM\01FEN1.SGM
01FEN1
]]>Agencies
[Federal Register Volume 86, Number 19 (Monday, February 1, 2021)]
[Notices]
[Page 7725]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-02093]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Statement of Organization, Functions, and Delegations of
Authority
Part C (Centers for Disease Control and Prevention) of the
Statement of Organization, Functions, and Delegations of Authority of
the Department of Health and Human Services (45 FR 67772-76, dated
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as
amended most recently at 86 FR 6336-6340, dated January 20, 2021) is
amended to reflect the Order of Succession for the Centers for Disease
Control and Prevention.
Section C-C, Order of Succession, is hereby amended as follows:
Delete in its entirety Section C-C, Order of Succession, and insert
the following:
During the absence or disability of the Director, Centers for
Disease Control and Prevention (CDC), or in the event of a vacancy in
that office, the first official listed below who is available shall act
as Director, except that during a planned period of absence, the
Director may specify a different order of succession:
1. Principal Deputy Director
2. Chief Medical Officer
3. Deputy Director for Public Health Service and Implementation Science
4. Deputy Director for Infectious Diseases
5. Deputy Director for Public Health Science and Surveillance
6. Deputy Director for Non-Infectious Diseases
7. Director, National Institute for Occupational Safety and Health
Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-02093 Filed 1-29-21; 8:45 am]
BILLING CODE 4160-18-P
